These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8145398)

  • 1. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension.
    Azuma I; Masuda K; Kitazawa Y; Takase M; Yamamura H
    Jpn J Ophthalmol; 1993; 37(4):514-25. PubMed ID: 8145398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
    Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
    Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of UF-021 (Rescula; isopropyl unoprostone).
    Yamamoto T; Kitazawa Y; Azuma I; Masuda K
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S99-103. PubMed ID: 9154284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
    Schenker H; Maloney S; Liss C; Gormley G; Hartenbaum D
    Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
    Sonty S; Mundorf TK; Stewart JA; Stewart WC
    Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group.
    Netland PA; Weiss HS; Stewart WC; Cohen JS; Nussbaum LL
    Am J Ophthalmol; 1997 Apr; 123(4):465-77. PubMed ID: 9124243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure.
    Stewart WC; Leland TM; Cate EA; Stewart JA
    J Glaucoma; 1998 Dec; 7(6):402-7. PubMed ID: 9871862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
    Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma.
    DuBiner HB; Hill R; Kaufman H; Keates EU; Zimmerman TJ; Mandell AI; Mundorf TK; Bahr RL; Schwartz LW; Towey AW; Hurvitz LM; Starita RJ; Sassani JW; Ropo A; Gunn R; Stewart WC
    Am J Ophthalmol; 1996 May; 121(5):522-8. PubMed ID: 8610795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD and 0.5% levobunolol hydrochloride BID in patients with ocular hypertension or open-angle glaucoma.
    Halper LK; Johnson-Pratt L; Dobbins T; Hartenbaum D
    J Ocul Pharmacol Ther; 2002 Apr; 18(2):105-13. PubMed ID: 12002664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma.
    Stewart WC; Dubiner HB; Mundorf TK; Laibovitz RA; Sall KN; Katz LJ; Singh K; Shulman DG; Siegel LI; Hudgins AC; Nussbaum L; Apostolaros M
    Am J Ophthalmol; 1999 Feb; 127(2):142-7. PubMed ID: 10030554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension].
    Kitazawa Y; Araie M;
    Nippon Ganka Gakkai Zasshi; 2011 Jun; 115(6):495-507. PubMed ID: 21735753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension.
    Kanno M; Araie M; Masuda K; Takase M; Kitazawa Y; Shiose Y; Azuma I; Ogawa N; Ohdo S
    Arzneimittelforschung; 2006; 56(11):729-34. PubMed ID: 17220049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
    McCarey BE; Kapik BM; Kane FE;
    Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension.
    Vold SD; Evans RM; Stewart RH; Walters T; Mallick S
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):601-5. PubMed ID: 19049301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.